Markets:

Overview

News

Currencies

International

Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises Over 3% ↗

August 23, 2021

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings...

Via Benzinga

Topics Stocks

58 Biggest Movers From Friday ↗

August 23, 2021

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter...

Via Benzinga

Unusual Options Activity Insight: BeiGene ↗

August 11, 2021

BeiGene (NASDAQ:BGNE) shares experienced unusual options ...

Via Benzinga

BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China ↗

August 17, 2021

The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) - EUSA Pharma's (UK) ...

Via Benzinga

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients ↗

July 30, 2021

BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to...

Via Benzinga

62 Biggest Movers From Yesterday ↗

July 29, 2021

Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to...

Via Benzinga

Topics Cannabis

Why BeiGene Stock Soared Today ↗

July 28, 2021

A regulatory filing gave a sneak peek at the company's second-quarter sales.

Via The Motley Fool

Topics Regulatory Compliance

Chinese Stock Crash ↗

July 26, 2021

For a second week in a row, we saw a big drop in stocks on Monday, while the Delta virus variant was blamed for the selloff last week, this week the cause is a big Beijing regulatory crackdown on...

Via Talk Markets

BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma ↗

July 26, 2021

Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at...

Via Benzinga

Yellow Card ↗

July 12, 2021

The price of oil fell about 1% today.

Via Talk Markets

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients ↗

July 09, 2021

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The...

Via Benzinga

PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer ↗

July 07, 2021

PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership...

Via Benzinga

Fireworks Display ↗

July 05, 2021

The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.

Via Talk Markets

Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market ↗

July 03, 2021

BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US.

Via Talk Markets

Topics Initial Public Offering

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

Is This Chinese Biopharma Stock Still a Buy? ↗

June 28, 2021

The pharmaceutical company had a solid first quarter and boasts a nice pipeline.

Via The Motley Fool

Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development ↗

June 26, 2021

Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and...

Via Talk Markets

Topics Artificial Intelligence

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street ↗

June 21, 2021

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National...

Via Benzinga

Topics Economy Stocks

5 Stocks To Watch For June 21, 2021 ↗

June 21, 2021

Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning...

Via Benzinga

Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion ↗

June 19, 2021

Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...

Via Talk Markets

Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO ↗

June 12, 2021

Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin...

Via Talk Markets

Topics Initial Public Offering

BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica ↗

June 11, 2021

BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (...

Via Benzinga

BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer ↗

June 09, 2021

Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a...

Via Benzinga

The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex ↗

June 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...

Via Benzinga

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal ↗

May 22, 2021

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200...

Via Talk Markets

BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer ↗

May 21, 2021

BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a...

Via Benzinga

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

Headline News about BeiGene, Ltd. - American Depositary Shares

Starting at $3.75/week.

Subscribe Today